| abstract |
An antibody directed against isolated human TNFα, for use in the treatment of suppurative hydradenitis (HS) in a subject, in which the isolated human anti-TNFα antibody is administered to the subject according to a multiple variable dose regimen comprising: a) a first loading dose of 160 mg at week 0, b) a second loading dose of 80 mg at week 2, and c) a weekly treatment dose of 40 mg from week 4; additionally in which the anti-TNFα antibody is adalimumab. |